PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 25, 2026Cancer Gene Therapy0 citationsOpen Access

LMTK3 regulates breast cancer angiogenesis via a context-dependent mesenchymal-epithelial transition program

View Full Paper
JLJian LuXHXiaoyan HuangHYHang Yao

Key Points

  • To explore the role of LMTK3 in regulating angiogenesis within the breast cancer microenvironment.
  • Utilized single-cell RNA sequencing to analyze gene expression.
  • Conducted functional validation to assess LMTK3's role.
  • Explored effects in mesenchymal-like triple-negative breast cancer (TNBC) and luminal-like cells.
  • Found that LMTK3 promotes a pro-angiogenic state in mesenchymal-like TNBC through sustained ERK signaling.
  • Identified that LMTK3 enforces a hyperepithelialized state in luminal-like cells, suppressing angiogenesis.
  • Demonstrated LMTK3's dual role in regulating angiogenic plasticity.

Abstract

Abstract Angiogenesis constitutes a critical rate-limiting determinant of tumor progression in breast cancer (BC). Resistance to conventional anti-angiogenic therapies in BC highlights an unmet need to identify upstream molecular regulators coordinating malignant cell plasticity and vascular remodeling. Lemur tail kinase 3 (LMTK3) is a well-established oncogenic kinase; however, its specific role within the tumor angiogenic microenvironment remains undefined. Here, we identify LMTK3 as a context-dependent driver of angiogenesis through a mesenchymal-epithelial transition (MET) program. By integrating single-cell RNA sequencing with functional validation, we uncover a ‘Simpson’s paradox’ (where a correlation present in different groups disappears or reverses when combined): In mesenchymal-like triple-negative breast cancer (TNBC), LMTK3 promotes a pro-angiogenic, ‘partial EMT’ (p-EMT) state characterized by sustained ERK signaling and elevated secretion of angiogenic factors, including angiogenin. Conversely, in luminal-like cells, LMTK3 enforces a hyperepithelialized state that suppresses angiogenic phenotypes. Consequently, LMTK3 emerges as a central regulator of angiogenic plasticity, and its targeted inhibition offers a promising strategy to abrogate the pro-angiogenic p-EMT state and promote vascular normalization in TNBC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lu et al. (2026) studied this question.

synapsesocial.com/papers/6975b4fd5a65d392b01e5beehttps://doi.org/10.1038/s41417-026-01001-2
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Regulatory Element in the Intrinsically Disordered C-Terminal Region of LMTK3 Modulates Its Kinase Domain Interactions and Breast Cancer Phenotypes2026
  2. 2Abstract 443: LMTK2: A novel driver of endocrine resistance in ERα+ breast cancer.2026
  3. 3Abstract 6832: Gender specific role of LMTK3 in neuronal-tumor microenvironment crosstalk in CRC2024
  4. 4Abstract PS2-11-01: Lmtk2: a novel driver of endocrine resistance in ER+ breast cancer2026
  5. 5Abstract PO1-25-01: LMTK3 promotes macrophage M2 polarisation and suppresses monocyte infiltration in breast cancer by altering the proteomic cargo of exosomes2024